Study guide

10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption

Key Takeaways Explain This Topic AI

Thiopurine methyltransferase activity must be measured before starting azathioprine or mercaptopurine, because deficiency causes profound myelosuppression.

Coeliac serology requires the patient to be eating gluten and requires total IgA measurement, since selective IgA deficiency causes false-negative tissue transglutaminase results.

Aminosalicylates maintain remission in ulcerative colitis but have little role in maintaining remission in Crohn's disease.

Last updated: September 2026

  • 3. Medical Management of Inflammatory Bowel Disease
  • Crohn's Disease Management

Induction of Remission (Mild-to-Moderate): Oral budesonide (9 mg once daily for 8 weeks) is preferred for mild-to-moderate ileocaecal disease; high first-pass hepatic clearance (~90%) confers lower systemic glucocorticoid toxicity. For more widespread disease, oral prednisolone (40 mg daily, tapered by 5 mg weekly over 8 weeks). Exclusive enteral nutrition (EEN) is an established first-line alternative, especially in paediatric and adolescent populations.

Induction of Remission (Moderate-to-Severe / Refractory): Intravenous hydrocortisone (100 mg QDS) or early biologic therapy: Infliximab (chimeric monoclonal anti-TNF-alpha antibody), Adalimumab (fully human anti-TNF), Ustekinumab (anti-IL-12/23 p40 subunit), or Vedolizumab (gut-selective alpha-4-beta-7 integrin antagonist). Pre-biologic safety mandate: Must screen for latent tuberculosis (chest radiograph and interferon-gamma release assay [IGRA]) and chronic viral hepatitis (HBV/HCV serology) before commencing anti-TNF therapy.

Maintenance of Remission:

Thiopurines: Oral Azathioprine (2.0–2.5 mg/kg/day) or Mercaptopurine (1.0–1.5 mg/kg/day). Critical safety requirement: Measure thiopurine methyltransferase (TPMT) enzymatic activity or genotype prior to initiating therapy. Individuals with homozygous mutations or negligible TPMT activity (<10%) metabolize thiopurines via hypoxanthine phosphoribosyltransferase (HPRT) into excessive, toxic levels of 6-thioguanine nucleotides (6-TGN), triggering catastrophic, potentially fatal bone marrow aplasia . Regular FBC and LFT monitoring is mandatory.

Methotrexate: Intramuscular or subcutaneous weekly injection (with oral folic acid) is an effective maintenance agent for azathioprine-intolerant CD patients. Strictly teratogenic.

Note on 5-ASAs: Mesalazine and sulfasalazine have no proven role in the maintenance of remission in Crohn's disease.

Ulcerative Colitis Management

Mild-to-Moderate Proctitis: First-line therapy is topical mesalazine (5-ASA) suppositories (1 g once daily). Topical 5-ASA is clinically superior to oral 5-ASA and superior to topical corticosteroids for inducing and maintaining proctitis remission.

Mild-to-Moderate Left-Sided or Extensive Colitis: Combined high-dose oral 5-ASA (e.g., mesalazine 2.4–4.8 g daily) plus topical 5-ASA enema (1 g/day). If inadequate clinical improvement within 2–4 weeks, add oral prednisolone (40 mg daily tapering over 8 weeks).

Maintenance of Remission: Lifelong oral 5-ASA (mesalazine 1.6–2.4 g daily). Thiopurines (azathioprine) or biologics are escalated if frequent relapses occur.

Acute Severe Ulcerative Colitis (ASUC) — Emergency Protocol

Acute severe ulcerative colitis is a life-threatening medical emergency requiring immediate hospital admission to a specialist gastroenterology unit.

Truelove and Witts Criteria for Severe Colitis

Diagnosis requires meeting the mandatory stool frequency criterion plus at least one marker of systemic toxicity :

  • Clinical / Laboratory Parameter Mild Ulcerative Colitis Severe Ulcerative Colitis (Truelove & Witts)
  • Stool Frequency <4 bowel motions per day >=6 bloody bowel motions per day (MANDATORY)
  • Temperature Afebrile (<37.5°C) >37.8°C (on >=2 out of 4 days)
  • Pulse Rate Normal (<90 bpm) >90 bpm
  • Haemoglobin Normal (>115 g/L) <105 g/L (or requiring transfusion)
  • Erythrocyte Sedimentation Rate (ESR) <20 mm/hour >30 mm/hour
  • C-Reactive Protein (CRP) Normal (<10 mg/L) >45 mg/L
  • Emergency Inpatient Management Algorithm

Immediate Resuscitation & Medical Measures:

Intravenous crystalloid fluid replacement and aggressive correction of electrolyte disturbances, specifically hypokalaemia and hypomagnesaemia (hypokalaemia paralyzes colonic smooth muscle, predisposing to toxic megacolon).

Intravenous Hydrocortisone 100 mg four times daily (or IV methylprednisolone 60 mg daily).

Thromboprophylaxis: Administer prophylactic low-molecular-weight heparin (LMWH) subcutaneously to all inpatients. Critical Exam Trap: Never withhold heparin because of visible rectal bleeding; ASUC confers a massive risk of fatal pulmonary embolism.

Diagnostic Tests: Stool microscopy, culture, and Clostridioides difficile toxin PCR to rule out superinfection. Unprepared, gentle flexible sigmoidoscopy with minimal air insufflation to confirm severe mucosal ulceration and biopsy for cytomegalovirus (CMV) inclusion bodies.

Contraindicated Drugs: Strictly discontinue all antidiarrhoeal antimotility agents (loperamide, diphenoxylate, codeine phosphate), NSAIDs, and anticholinergics, as they precipitate acute colonic dilatation.

Monitoring: Daily clinical assessment, twice-daily vital signs, serial CRP, and daily plain abdominal radiography to monitor colonic calibre. Toxic megacolon is defined radiologically as non-obstructive transverse colon dilatation >6.0 cm with loss of haustrations, mucosal islands, and systemic toxicity.

Day 3–5 Assessment (Oxford Criteria): Patients exhibiting stool frequency >8 per day OR stool frequency 4–8 per day combined with CRP >45 mg/L on Day 3 of IV corticosteroid therapy have an ~85% likelihood of failing medical therapy and requiring colectomy.

Second-Line Rescue Therapy: If no objective improvement by Day 3–5, initiate rescue medical therapy:

Infliximab: Monoclonal anti-TNF antibody (5 mg/kg IV infusion; accelerated dosing 10 mg/kg in hypoalbuminaemic patients due to rapid faecal drug loss).

Ciclosporin: Calcineurin inhibitor administered as a continuous IV infusion (2 mg/kg/day targeting whole blood trough levels of 150–250 ng/mL). Requires normal renal function and screening for hypomagnesaemia (hypomagnesaemia lowers seizure threshold).

Emergency Surgical Indications: Failure of rescue medical therapy within 48–72 hours, toxic megacolon unresponsive to decompression within 24 hours, colonic perforation, or torrential lower GI bleeding dictates emergency subtotal colectomy with end-ileostomy and preservation of the rectal stump.

  • 4. Malabsorption & Coeliac Disease
  • Pathophysiology & Genetic Architecture

Coeliac disease is an immune-mediated systemic enteropathy triggered by the dietary ingestion of gluten (specifically the alcohol-soluble gliadin fraction found in wheat, barley, and rye) in genetically susceptible individuals.

Genetics: Virtually all patients express Human Leukocyte Antigen (HLA) Class II heterodimers: HLA-DQ2 (encoded by DQA1*05:01 and DQB1*02:01, present in ~95% of patients) or HLA-DQ8 (present in ~5%). HLA testing carries an exceptional negative predictive value (>99%) ; the absence of both HLA-DQ2 and HLA-DQ8 virtually excludes coeliac disease.

Immunological Cascade: Luminal gliadin peptides resist gastric and pancreatic enzymatic digestion. Gliadin crosses the mucosal barrier into the lamina propria, where it is deamidated by the enzyme tissue transglutaminase (tTG) . Deamidation introduces negative charges, allowing gliadin peptides to dock with high affinity into the positively charged binding grooves of HLA-DQ2/DQ8 on antigen-presenting dendritic cells. These stimulate CD4+ T helper cells to produce proinflammatory cytokines (interferon-gamma, IL-21), triggering intraepithelial CD8+ cytotoxic T-cell activation and massive enterocyte apoptosis.

Diagnostic Evaluation & Serology

Prerequisite Dietary Requirement: Patients must consume a gluten-containing diet (at least one gluten-containing meal daily for a minimum of 6 weeks) before diagnostic testing. Initiating a gluten-free diet prior to testing causes rapid serological clearance and mucosal healing, yielding false-negative serology and histology .

Serological Testing Algorithm:

First-Line Test: Total Serum IgA + Anti-Tissue Transglutaminase IgA (anti-tTG IgA). Anti-tTG IgA possesses sensitivity and specificity >95%.

Selective IgA Deficiency Rule: The incidence of selective IgA deficiency is 10- to 15-fold higher in patients with coeliac disease (~2–3%) compared to the general population (1 in 600). If total serum IgA is low or undetectable (<0.2 g/L), anti-tTG IgA will be falsely negative. In this scenario, IgG-based serology must be performed: IgG anti-tissue transglutaminase (anti-tTG IgG) or IgG deamidated gliadin peptide (anti-DGP IgG) .

Anti-Endomysial Antibody (EMA IgA): Indirect immunofluorescence assay targeting intermyofibrial connective tissue; highly specific (>99%) and utilized as a secondary confirmatory marker.

Upper GI Endoscopy & Small Bowel Biopsy: Remains the diagnostic gold standard in adults. Endoscopic inspection of the duodenum reveals scalloped mucosal folds, mosaic "cracked-mud" mucosal pattern, and micronodularity. At least four biopsies from the second/third part of the duodenum (D2/D3) plus at least two biopsies from the duodenal bulb must be taken, as mucosal lesions are frequently patchy.

The Marsh Histopathological Classification

  • Marsh Stage Histological Description Structural Architecture
  • Marsh 0 (Pre-infiltrative) Normal small intestinal architecture Normal enterocytes and villi; normal IEL count

Marsh 1 (Infiltrative) Intraepithelial lymphocytosis >25 intraepithelial lymphocytes (IELs) per 100 enterocytes ; villi and crypts normal

Marsh 2 (Hyperplastic) Crypt hyperplasia Intraepithelial lymphocytosis + elongation and deepening of crypts ; normal villi

Marsh 3a (Destructive - Partial) Partial villous atrophy Intraepithelial lymphocytosis + crypt hyperplasia + marked blunting of villous tips

Marsh 3b (Destructive - Subtotal) Subtotal villous atrophy Marked crypt hyperplasia + attenuated, stunted, rudimentary villi

Marsh 3c (Destructive - Total) Total villous atrophy Complete absence of mucosal villi (flat mucosa) ; deep, hyperplastic crypts

Systemic Manifestations, Associated Conditions & Complications

Clinical Presentation: Steatorrhoea, chronic osmotic diarrhoea, bloating, flatulence, recurrent abdominal pain, weight loss, and failure to thrive in children. Atypical presentations dominate in adults: unexplained isolated iron deficiency anaemia (microcytic anaemia refractory to oral iron, as iron is absorbed in the damaged proximal duodenum), folate deficiency, fatigue, recurrent aphthous stomatitis, and elevated transaminases ("coeliac hepatitis").

Associated Autoimmune Disorders: Type 1 Diabetes Mellitus, autoimmune thyroid disease (Hashimoto's/Graves'), primary biliary cholangitis, Sjögren's syndrome, Down syndrome, and Turner syndrome.

Metabolic Bone Disease (Osteoporosis): Impaired absorption of fat-soluble vitamin D and calcium secondary to proximal villous blunting. All newly diagnosed adults mandate baseline DEXA bone densitometry and supplemental calcium and vitamin D.

Hyposplenism (Splenic Atrophy): Occurs in up to one-third of adult coeliac patients. Peripheral blood film characteristically shows Howell-Jolly bodies (nuclear remnants in erythrocytes), target cells, and Pappenheimer bodies. Patients have heightened susceptibility to encapsulated pathogens and mandate immunization against Streptococcus pneumoniae , Neisseria meningitidis (groups A, C, W, Y), and Haemophilus influenzae type b (Hib) , alongside annual influenza vaccination.

Malignancy Risk: Long-term untreated coeliac disease confers a significantly increased risk of gastrointestinal malignancies, most notably Enteropathy-Associated T-Cell Lymphoma (EATL) —a rare, highly aggressive, high-grade non-Hodgkin lymphoma arising from intraepithelial T lymphocytes in the jejunum. Presents with fever, anorexia, weight loss, recurrent abdominal pain, and small bowel perforation in patients with refractory coeliac disease. Also elevates risk of small intestinal adenocarcinoma and squamous cell carcinoma of the oesophagus.

Dermatitis Herpetiformis: Cutaneous manifestation of coeliac disease characterized by intensely pruritic, grouped, polymorphic erythematous papules and vesicles distributed symmetrically over extensor surfaces (elbows, knees, buttocks, scalp). Direct immunofluorescence of perilesional skin demonstrates pathognomonic granular IgA deposition in the dermal papillae . Management comprises oral dapsone for rapid symptomatic relief of pruritus (mandates baseline G6PD screening and monitoring for haemolytic anaemia and methaemoglobinaemia) combined with a lifelong strict gluten-free diet , which heals the underlying mucosal enteropathy and allows dapsone discontinuation.